Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
72 hedge funds and large institutions have $8.76M invested in Elevation Oncology in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 12 closing their positions.
1,600% more call options, than puts
Call options by funds: $17K | Put options by funds: $1K
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
1% more funds holding
Funds holding: 71 → 72 (+1)
10.46% less ownership
Funds ownership: 67.61% → 57.16% (-10%)
18% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 22
61% less capital invested
Capital invested by funds: $22.5M → $8.76M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.36M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$250K |
| 3 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$119K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$91.6K |
| 5 |
Two Sigma Advisers
New York
|
+$62.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.98M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.67M |
| 3 |
Goldman Sachs
New York
|
-$899K |
| 4 |
Renaissance Technologies
New York
|
-$546K |
| 5 |
O
OrbiMed
New York
|
-$530K |
ELEV Hedge Fund Activity: Q1 2025 in Review
72 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q1 2025, worth a combined $8.76M — down 61% from $22.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ELEV positions and 12 closed out — a net gain of 2 holders — while 18 added to existing stakes and 22 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $3.36M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $1.98M sold.
- 72 institutional investors held Elevation Oncology (ELEV) as of Q1 2025, up from 71 in Q4 2024.
- Funds reported $8.76M of Elevation Oncology stock for Q1 2025, down 61% quarter-over-quarter.
- 14 funds opened new Elevation Oncology positions in Q1 2025 and 12 closed out, a net change of +2 holders.
- The largest Elevation Oncology buyer in Q1 2025 was BML Capital Management, an estimated $3.36M added.
- The largest Elevation Oncology seller in Q1 2025 was Farallon Capital Management, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2025.